文献速递MDS 与骨髓增殖性肿瘤白血病

靶向基因测序在鉴别髓系恶性肿瘤与其他血细胞减少症中的效用

Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
PubMed 文献 · Blood Adv · 2023-01-01

美国国家心肺血液研究所资助的国家MDS自然史研究(NCT02775383)为前瞻性队列研究,纳入疑似MDS的血细胞减少患者,对1298例患者骨髓样本测序53个基因,基于18个基因突变谱构建两阶段诊断分类器,区分髓系恶性肿瘤与非髓系恶性肿瘤、以及MDS与非MDS恶性肿瘤。

要点

  • 分类器区分髓系恶性肿瘤与非髓系恶性肿瘤的PPV为0.84、NPV为0.8,AUROC为0.85。
  • 分类器区分MDS与非MDS恶性肿瘤的PPV为0.71、NPV为0.64,AUROC为0.73。
  • 在局部与中心病理意见不一致的139例中,99例(71%)分类器预测与第三方病理复核一致。

核心结论

  • 基于18个基因突变谱的两阶段诊断分类器可辅助组织病理学,提高髓系恶性肿瘤与MDS的诊断准确性。

研究设计与样本

  • 国家MDS自然史研究(NCT02775383)为前瞻性队列研究,纳入疑似MDS的血细胞减少患者。
  • 对1298例诊断为髓系恶性肿瘤(包括MDS、非MDS髓系恶性肿瘤或伴血细胞减少的其他骨髓情况)患者的骨髓样本测序53个基因,诊断依据局部、中心及必要时第三方病理复核的一致性。

主要发现

  • 基于17个基因VAF区分髓系与非髓系恶性肿瘤时,PPV为0.84、NPV为0.8,AUROC为0.85。
  • 基于10个基因VAF区分MDS与非MDS恶性肿瘤时,PPV为0.71、NPV为0.64,AUROC为0.73。
  • 局部与中心病理在髓系与非髓系恶性肿瘤判断上不一致的139例中,99例(71%)分类器预测诊断与第三方病理复核一致,PPV为0.83、NPV为0.65。

关键数值与推荐

  • 分类器基于53个测序基因中的18个基因突变谱构建,为两阶段诊断分类器。
  • 髓系与非髓系恶性肿瘤分类使用17个基因的VAF,PPV 0.84、NPV 0.8、AUROC 0.85。
  • MDS与非MDS恶性肿瘤分类使用10个基因的VAF,PPV 0.71、NPV 0.64、AUROC 0.73。
  • 病理不一致病例中分类器与第三方病理复核的一致情况:139例中99例(71%),PPV 0.83、NPV 0.65。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The National Heart, Lung, and Blood Institute-funded National MDS Natural History Study (NCT02775383) is a prospective cohort study enrolling patients with cytopenia with suspected myelodysplastic syndromes (MDS) to evaluate factors associated with disease. Here, we sequenced 53 genes in bone marrow samples harvested from 1298 patients diagnosed with myeloid malignancy, including MDS and non-MDS myeloid malignancy or alternative marrow conditions with cytopenia based on concordance between independent histopathologic reviews (local, centralized, and tertiary to adjudicate disagreements when needed). We developed a novel 2-stage diagnostic classifier based on mutational profiles in 18 of 53 sequenced genes that were sufficient to best predict a diagnosis of myeloid malignancy and among those with a predicted myeloid malignancy, predict whether they had MDS. The classifier achieved a positive predictive value (PPV) of 0.84 and negative predictive value (NPV) of 0.8 with an area under the receiver operating characteristic curve (AUROC) of 0.85 when classifying patients as having myeloid vs no myeloid malignancy based on variant allele frequencies (VAFs) in 17 genes and a PPV of 0.71 and NPV of 0.64 with an AUROC of 0.73 when classifying patients as having MDS vs non-MDS malignancy based on VAFs in 10 genes. We next assessed how this approach could complement histopathology to improve diagnostic accuracy. For 99 of 139 (71%) patients (PPV of 0.83 and NPV of 0.65) with local and centralized histopathologic disagreement in myeloid vs no myeloid malignancy, the classifier-predicted diagnosis agreed with the tertiary pathology review (considered the internal gold standard).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. DeZern AE, Goll JB, Lindsley RC, et al. Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions. Blood Adv. 2023. PMID: 36947201. doi:10.1182/bloodadvances.2022008578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。